Key facts
- This page summarizes William Fricker's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2021, 18:46.
William Fricker - 24 May 2021 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)
- Reporting relationship
- CFO & Treasurer
- Issuer ticker
- NRXP
- Reported as of
- 24 May 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ William Fricker
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
William Fricker filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 10 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRXP
transaction
Derivative
Employee Stock Option (Right to buy)
Award
- Transaction value
- Shares
- +99,200
- Change %
- Price
- Shares after
- 99,200
- Date
- 24 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,200
- Exercise price
- $3.08
- Footnotes
- F1
NRXP
transaction
Derivative
Employee Stock Option (Right to buy)
Award
- Transaction value
- Shares
- +99,200
- Change %
- +100%
- Price
- Shares after
- 198,400
- Date
- 24 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,200
- Exercise price
- $3.08
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement).
Footnote F2
Subject to certain conditions, the options will generally vest in 36 equal installments every month commencing on 11/30/20 and fully vesting on 11/30/23.